TABLE 3.
Changes in patients’ characteristics before and after orlistat or ezetimibe intervention.
| Characteristics | Orlistat | Ezetimibe | ||||
|---|---|---|---|---|---|---|
| Before intervention | After intervention | p-value | Before intervention | After intervention | p-value | |
| BW (kg) | 80.574 ± 11.574 | 80.058 ± 11.484 | 0.551a | 84.108 ± 15.508 | 83.561 ± 14.652 | 0.198a |
| BMI (kg/m2) | 28.938 ± 3.618 | 28.805 ± 4.011 | 0.701a | 30.272 ± 4.117 | 30.099 ± 3.919 | 0.250a |
| WC (cm) | 98.604 ± 11.926 | 96.944 ± 11.216 | 0.021a | 101.942 ± 11.935 | 101.163 ± 11.567 | 0.147a |
| HC (cm) | 105.059 ± 8.549 | 104.666 ± 8.385 | 0.180a | 107.577 ± 10.221 | 107.094 ± 9.192 | 0.527a |
| FBG (mmol/L) | 5.440 ± 2.306 | 5.001 ± 1.434 | 0.013b | 5.865 ± 2.194 | 5.668 ± 1.942 | 0.869b |
| TG (mmol/L) | 3.809 ± 2.467 | 3.127 ± 2.645 | 0.028b | 3.578 ± 2.568 | 2.455 ± 1.688 | 0.005b |
| TC (mmol/L) | 4.941 ± 1.718 | 4.762 ± 1.001 | 0.515a | 5.277 ± 0.977 | 4.509 ± 0.833 | <0.0001a |
| LDL-C (mmol/L) | 3.138 ± 1.179 | 3.197 ± 0.802 | 0.740a | 3.495 ± 0.712 | 3.133 ± 0.616 | 0.007a |
| HDL-C (mmol/L) | 1.124 ± 0.450 | 1.126 ± 0.231 | 0.565b | 1.157 ± 0.365 | 1.165 ± 0.314 | 0.903b |
| γ-GT (U/L) | 47.499 ± 29.959 | 52.318 ± 32.968 | 0.750b | 44.397 ± 27.850 | 46.301 ± 29.281 | 0.819b |
| ALT (U/L) | 32.261 ± 23.242 | 30.303 ± 23.396 | 0.491b | 35.885 ± 26.338 | 30.957 ± 19.018 | 0.603b |
| AST (U/L) | 26.293 ± 11.281 | 24.796 ± 13.974 | 0.237b | 24.242 ± 12.751 | 22.601 ± 9.846 | 0.486a |
| ALB (g/L) | 44.161 ± 7.434 | 41.656 ± 5.258 | 0.072b | 42.422 ± 5.077 | 42.704 ± 6.598 | 0.476b |
Data were presented as mean ± standard deviation or n (%).
a
Paired t-test.
b
Wilcoxon matched pairs signed rank test.